Accessibility Menu
InterCure logo

InterCure(NASDAQ) INCR

Market Cap$56.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-61%
5 Year-85%
1 Year-36%
1 Month-1%
$0.97
+4.82%
+0.04Today
InterCure last closing stock price
MetricPriceDate
Last closeUSD 0.962026-08-10
InterCure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.75%USD 0.952026-08-03
1 month-1.03%USD 0.972026-07-10
3 month+18.52%USD 0.812026-05-12
Year to date+5.49%USD 0.912025-12-31
1 year-36%USD 1.502025-08-08
3 year-36%USD 1.502023-08-11
5 year-84.52%USD 6.202021-08-11
Since inception-60.96%USD 2.512019-01-28

InterCure Financials at a Glance

Market Cap

$56.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

₪270.20M

Net Income (TTM)

-₪35.71M

EPS (TTM)

-$0.20

P/E Ratio

-4.80

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$0.97

Volume

3,230

Open

$0.95

Previous Close

$0.96

Daily Range

$0.95 - $0.99

52-Week Range

$0.68 - $1.76

Estimated Earnings Date

Jul 30, 2026

INCR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InterCure

InterCure Ltd. is a leading player in the medical cannabis industry, involved in the entire lifecycle of cannabis products from research and cultivation to manufacturing and global distribution. The company operates primarily in the Israeli market while also expanding its reach internationally.

Products and Services
  • Dried cannabis flower and cannabis extracts infused with oil
  • Investment in the biomedical sector
  • Comprehensive supply chain management for cannabis products
Growth Outlook
  • Revenue of 70,094,500 ILS in Q4 2025, indicating strong market demand
  • Gross profit margin improved to 30.9% in Q2 2025, showcasing operational efficiency
  • Continued expansion into international markets expected to drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of 25,000,000 ILS, reflecting a solid revenue base
  • Operating income margin of -23.5% in Q4 2025, indicating room for improvement
  • Cash and cash equivalents of 46,466,000 ILS as of Q4 2025, providing liquidity
InterCure Ltd. has established itself as a significant entity in the medical cannabis sector, with a diverse product range and a commitment to quality. The company's recent financial performance shows promising revenue growth, particularly in the last quarter, which may attract investor interest. The improvement in gross profit margin suggests that operational efficiencies are being realized, which could enhance profitability in the future. With a strong cash position, InterCure is well-positioned to capitalize on growth opportunities in both domestic and international markets.
AI Generated • Jul 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

285

CEO

Alexander Rabinovitch

Website

www.intercure.co

Headquarters

Herzliya, TA 4676670, IL

INCR Financials

Key Financial Metrics (TTM)

Gross Margin

15.06%

Operating Margin

-10.08%

Net Income Margin

-13.22%

Return on Equity

-8.63%

Return on Capital

1.16%

Return on Assets

-5.17%

Earnings Yield

-20.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$56.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

59.23M

Volume

3.23K

Avg. Volume

46.77K

Financials (TTM)

Gross Profit

₪40.70M

Operating Income

-₪27.24M

EBITDA

-₪55.34M

Operating Cash Flow

₪31.36M

Capital Expenditure

-₪6.95M

Free Cash Flow

₪24.41M

Cash & ST Invst.

₪46.68M

Total Debt

₪183.01M

InterCure Performance Analysis

InterCure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31ILS 115,681,89070.1%
20232023-12-31ILS 96,407,734-16.7%
20242024-12-31ILS 64,523,457-33.1%
20252025-12-31ILS 78,336,40321.4%
InterCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3114.9%
Q22025-06-30N/A
Q32025-09-307.8%
Q42025-12-31N/A
InterCure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31ILS 0.29725.3%
20232023-12-31ILS -0.37N/A
20242024-12-31ILS -0.408.3%
20252025-12-31ILS -0.19-51.8%
InterCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3198.1%
Q22025-06-30N/A
Q32025-09-30-2166.7%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

₪70.09M

+23.9%

Gross Profit

₪239.50K

+22.5%

Gross Margin

0.34%

N/A

Market Cap

$56.86MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$199.51K

N/A

Employees

285

N/A

Net Income

-₪17.00M

+50.9%

EBITDA

-₪34.80M

+25.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

₪46.68M

-40.7%

Total Debt

₪183.01M

-13.4%

Accounts Receivable

₪154.47M

-14.4%

Inventory

₪108.06M

-13.8%

Long Term Debt

₪78.95M

-42.4%

Short Term Debt

₪104.06M

+40.2%

Return on Assets

-5.17%

N/A

Return on Invested Capital

-5.72%

N/A

Free Cash Flow

₪13.29M

N/A

Operating Cash Flow

₪16.84M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HYFTMindWalk Holdings Corp.
$1.36+3.82%
CAMPCAMP4 Therapeutics Corporation
$4.22-0.47%
FBIOFortress Biotech, Inc.
$2.75+3.00%
BMEABiomea Fusion, Inc.
$1.27+0.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$73.80-0.01%
INTCIntel
$97.52-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.73+0.01%
SPCXSpace Exploration Technologies
$138.74+0.04%

Questions About INCR

What is the current price of InterCure?

InterCure is trading at $0.96 per share.

What is the 52-week range for InterCure?

Over the past 52 weeks, InterCure has traded between $0.68 and $1.76.

How much debt does InterCure have?

As of the most recent reporting period, InterCure reported total debt of ₪57.42M.

How much cash does InterCure have on hand?

InterCure reported ₪15.22M in cash and cash equivalents in its most recent financial results.

What is InterCure’s dividend yield?

InterCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services